
Replek offers medicines, food supplements, and medical devices across research, production, quality control, registration, and distribution.
replek.mkCrawled Nov 16, 2026
Replek is a Macedonian pharmaceutical company with over 80 years of tradition, producing health and wellness products available in more than 25 countries.
Replek participates in CPHI, a major pharmaceutical trade fair in Milan, to expand its global partnerships. The company showcases its export potential to over 62,000 attendees from 166 countries. This marks its fifth consecutive year at the event, reinforcing business cooperation with international markets.
Replek AD Skopje reports a **24% year-over-year increase in domestic pharmaceutical sales**, reaching **4.8 million euros** in the first half of 2026. The company’s total revenues in the segment hit **13.9 million euros**, driven primarily by domestic market performance. This growth strengthens its position in Macedonia’s pharmaceutical sector.
Replek introduces its manufacturing capabilities and export strategies to Ambassador Matthew Lawson during his visit. The company highlights its expansion into the British market and outlines plans for further growth. Lawson engages with Replek’s leadership to explore potential collaborations and trade opportunities.
Replek completes its first medical cannabis export to the European Union, marking a decade since launching its own manufacturing and development of cannabis-based pharmaceuticals in 2016. The company pioneered domestic production in its market and remains a leading regional player in the industry. This milestone highlights its growth amid rising industry demands for transparency and standardization.
Replek secures UK registration for **Rekonazol**, its first medicinal product—a 2% ketoconazole shampoo for dermatological treatments. The **Medicines and Healthcare products Regulatory Agency (MHRA)** grants marketing authorization, marking Replek’s official entry into the highly regulated British market. This milestone expands the company’s international portfolio beyond its existing markets.
Replek secures its fifth consecutive EU GMP certification, validating adherence to Europe’s strictest quality and manufacturing standards. The latest certification now covers three additional product forms—suppositories, vaginal tablets, and another unspecified form—expanding its production scope. The company highlights this milestone as proof of its commitment to continuous process improvements and operational reliability.
Replek AD Skopje reports a **39% profit increase in 2025**, reaching **€5 million** and boosting its net profit margin from **11.5% to 15%**. The company attributes gains to operational efficiency despite ongoing investments. Replek also emphasizes its **export expansion strategy** as part of sustained growth plans.